Efficacy and safety of desvenlafaxine in treating patients with major depressive disorder: a network meta-analysis
DVS at doses ≥ 50 mg/day significantly improves depressive symptoms compared with placebo. Among the evaluated doses, 200 mg/day consistently showed numerically greater improvements while maintaining acceptable tolerability; however, the certainty of dose differences remains limited, and no definitive "optimal" dose can be established based on the current evidence.
Authors
- Lingke Li (ORCID: https://orcid.org/0000-0002-0506-8659)
- Chenzhao Yuan (ORCID: https://orcid.org/0009-0008-5567-2505)
- Xiaodan Ren
Institutions
- Army Medical University (CN)
- Xinqiao Hospital (CN)
- Chiang Mai University (TH)
- Luoyang Institute of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Neuroscience
- Published
- 2026-02-06
- DOI
- https://doi.org/10.3389/fnins.2026.1721852
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00